Sveriges Riksbank
| Auction date | 2021-01-26 |
| Maturity | 2024 |
| Tendered volume, SEK mln | 1000 +/- 1000 |
| Offered volume, SEK mln | 0 |
| Volume bought, SEK mln | 0 |
| Number of bids | 0 |
| Number of accepted bids | 0 |
| Quarter | Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 |
| Offered volume, SEK mln | 0 | 0 | 0 | 0 |
| Volume bought, SEK mln | 0 | 0 | 0 | 0 |
| Number of bids | 0 | 0 | 0 | 0 |
| Number of accepted bids | 0 | 0 | 0 | 0 |
| Average yield, % | - | - | - | - |
| Lowest accepted yield, % | - | - | - | - |
| Highest yield, % | - | - | - | - |
| Accepted at lowest yield, % | - | - | - | - |
| Quarter | Quarter 1 | Quarter 2 | Quarter 3 | Quarter 4 |
| Offered volume, SEK mln | 0 | 0 | 0 | 0 |
| Volume bought, SEK mln | 0 | 0 | 0 | 0 |
| Number of bids | 0 | 0 | 0 | 0 |
| Number of accepted bids | 0 | 0 | 0 | 0 |
| Average yield, % | - | - | - | - |
| Lowest accepted yield, % | - | - | - | - |
| Highest yield, % | - | - | - | - |
| Accepted at lowest yield, % | - | - | - | - |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sveriges Riksbank17.10.2025 16:20:18 CEST | Press release
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS
Boehringer Ingelheim Limited17.10.2025 16:05:03 CEST | Press release
Boehringer’s zongertinib demonstrated a 77% objective response rate in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC
INTESA SANPAOLO S.P.A.17.10.2025 15:45:00 CEST | Press release
Intesa Sanpaolo's IMI Corporate & Investment Banking Division strengthens US role supporting transactions worth $50 billion in three years
Maytronics17.10.2025 15:00:00 CEST | Press release
Dolphin Liberty 600 by Maytronics Named to TIME’s List of the Best Inventions of 2025
Evaxion17.10.2025 14:15:51 CEST | Press release
Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom